Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration

Erin L. Rutherford, Laura Anne Lowery

Boston College, Department of Biology, 140 Commonwealth Avenue, Chestnut Hill, MA 02467, United States

ARTICLE INFO

Keywords: Wolf-Hirschhorn Syndrome Neural crest Cell migration Embryonic development

ABSTRACT

Wolf-Hirschhorn Syndrome (WHS) is a neurodevelopmental disorder characterized by mental retardation, craniofacial abnormalities, heart defects, skeletal defects, urogenital defects, and seizures (Battaglia et al., 2015; Cooper and Hirschhorn, 1961; Wolf et al., 1965). The most obvious and common clinical marker of WHS is the Greek warrior helmet appearance, caused by an abnormally wide nasal bridge attaching the nose to the forehead. WHS patients also exhibit a high forehead, drastic eyebrow arches, widely spaced eyes, a short philtrum, and micrognathia (undersized jaw). The vast majority of patients are microcephalic and have ears marked by abnormal positioning on the head and underdeveloped cartilage. Defects of the eye and optic nerve also occur in approximately 40% of patients. Many facial phenotypes can be classified as midline defects, including the common cleft palate. An overarching growth delay is also notable in WHS patients; the onset is prenatal in most and continues to manifest throughout early development, as patients’ stature is short and weight gain is slow (Battaglia et al., 2015). As the pathways responsible for brain development and craniofacial morphogenesis are linked (Braught et al., 2001; Marcucio et al., 2005), it is not surprising that a majority of WHS patients also exhibit mental retardation (Bergemann et al., 2005).

Each patient presents with a unique combination of WHS characteristics, with varying severity. Such clinical variability is the first reason that it has proven difficult to conduct research into the disorder’s underlying pathology. This review will focus on a second reason: WHS manifests at the genomic, epigenomic, and cell biological levels, and there is a lack of mechanistic knowledge regarding the exact effectors downstream of certain genetic mutations. Consequently, the field still lacks insights into appropriate initial questions to jumpstart investigations into the cell biological functions of WHS-related proteins. However, several players in the processes underlying the disorder have previously been described—for the most part, these are proteins which have established roles in routine epigenetic modifications, normal cellular metabolism, or in signaling pathways integral to proper development. From a few early studies, it has become clear that some of these epigenetic modifications and signaling events are connected to cell motility-related processes. Furthermore, the characteristic facial (and cardiac) phenotypes of WHS call to mind the neural crest, as most vertebrate facial features are derived from or influenced by the cranial subset of this multipotent stem cell population (Bronner and LeDouarin, 2012). Neural crest cells are born along the embryonic neural tube, and migrate long distances to reach their destinations, where they differentiate and contribute to structures such as peripheral nerves, jaw structures, facial cartilage, elements of the heart, and pigmented epidermal tissue (Bronner and LeDouarin, 2012). Considering both the morphological data detailing the WHS phenotype and recent cell biological studies exploring WHS candidate proteins, neural crest cell motility and migration are a promising avenue for investigation into WHS at the cell biological level.

1. Introduction

Wolf-Hirschhorn Syndrome (WHS) is a developmental disorder characterized by intellectual disability, craniofacial abnormalities, heart defects, skeletal defects, urogenital defects, and seizures (Battaglia et al., 2015; Cooper and Hirschhorn, 1961; Wolf et al., 1965). The most obvious and common clinical marker of WHS is the “Greek warrior helmet” appearance, caused by an abnormally wide nasal bridge attaching the nose to the forehead. WHS patients also exhibit a high forehead, drastic eyebrow arches, widely spaced eyes, a short philtrum, and micrognathia (undersized jaw). The vast majority of patients are microcephalic and have ears marked by abnormal positioning on the head and underdeveloped cartilage. Defects of the eye and optic nerve also occur in approximately 40% of patients. Many facial phenotypes can be classified as midline defects, including the common cleft palate. An overarching growth delay is also notable in WHS patients; the onset is prenatal in most and continues to manifest throughout early development, as patients’ stature is short and weight gain is slow (Battaglia et al., 2015). As the pathways responsible for brain development and craniofacial morphogenesis are linked (Braught et al., 2001; Marcucio et al., 2005), it is not surprising that a majority of WHS patients also exhibit mental retardation (Bergemann et al., 2005).

Each patient presents with a unique combination of WHS characteristics, with varying severity. Such clinical variability is the first reason that it has proven difficult to conduct research into the disorder's underlying pathology. This review will focus on a second reason: WHS manifests at the genomic, epigenomic, and cell biological levels, and there is a lack of mechanistic knowledge regarding the exact effectors downstream of certain genetic mutations. Consequently, the field still lacks insights into appropriate initial questions to jumpstart investigations into the cell biological functions of WHS-related proteins. However, several players in the processes underlying the disorder have previously been described—for the most part, these are proteins which have established roles in routine epigenetic modifications, normal cellular metabolism, or in signaling pathways integral to proper development. From a few early studies, it has become clear that some of these epigenetic modifications and signaling events are connected to cell motility-related processes. Furthermore, the characteristic facial (and cardiac) phenotypes of WHS call to mind the neural crest, as most vertebrate facial features are derived from or influenced by the cranial subset of this multipotent stem cell population (Bronner and LeDouarin, 2012). Neural crest cells are born along the embryonic neural tube, and migrate long distances to reach their destinations, where they differentiate and contribute to structures such as peripheral nerves, jaw structures, facial cartilage, elements of the heart, and pigmented epidermal tissue (Bronner and LeDouarin, 2012). Considering both the morphological data detailing the WHS phenotype and recent cell biological studies exploring WHS candidate proteins, neural crest cell motility and migration are a promising avenue for investigation into WHS at the cell biological level.
Following Hirschhorn’s initial characterization of a clinical phenotype in 1961, the major catalyst for research into WHS has been the definition of a critical genomic region (“critical region 1”), consisting of 165 kilobases on the short arm of chromosome four (the 4p region), which is deleted in traditional cases of the disorder (Wright et al., 1997; Fig. 1). The only characterized candidate genes that fall within this region are Wolf-Hirschhorn candidate 1 (WHSC1), referred to elsewhere as a multiple myeloma SET (MMSET) or nuclear receptor SET domain (NSD) protein, and WHSC2, which is also known as a negative elongation factor (NELF) (Wright et al., 1999). Despite lying entirely within the WHS critical region, WHSC2 has not emerged as one of the primary contributors to the WHS phenotype. While this may be due to a deficit in WHSC2-based studies, it also results from the identification of several patients with deletions telomeric to the critical region. As WHSC2 is left unaffected in these cases, they have called into question the gene’s clinical relevance (Bergemann et al., 2005; Cyr et al., 2011; Engbers et al., 2009; Zollino et al., 2014).

Deletions in the 4p region in most WHS patients encompass areas extending beyond the critical region, thus affecting several flanking genes including a transforming acidic coiled-coil gene (TACC3), a sequence encoding a fibroblast growth factor receptor (FGFR3), and the gene for a leucine zipper and EF-hand-containing transmembrane protein (LETM1), as listed in their sequential order with TACC3 most telomeric (Zollino et al., 2003). More recent genomic characterizations have revealed syntenies with genes found on chromosome 8p11.2 (Stec et al., 2001). It is clear that the FGFR-LETM-WHSC1 ordering is ancient, as it is conserved from fish to humans. Moreover, there are speculations as to whether this conserved region is larger, including TACC and NELF/WHSC2, and whether this particular grouping indicates some functional relationship (Stec et al., 2001). This review will explore the latter possibility by focusing on the WHSC1 protein encoded on chromosome 4p16.3 (where WHS mutations typically occur), as well as on FGFR3, LETM1, and TACC3, as these are presently the most promising candidates that may demonstrate a novel functional relationship based on neural crest cell motility in WHS (Table 1). Clinical variation in 4p deletion size has highlighted other candidates (Battaglia et al., 2015); however, a smaller group are explicitly linked to neural crest cell migration. WHSC1 is a 90 kb gene, two-thirds of which extend into the telomeric end of the 165 kb Wolf-Hirschhorn Syndrome Critical Region. It contains 25 exons and is subject to complex alternative splicing (Stec et al., 1998). Northern blot analysis of expression patterns in human and mouse embryonic and fetal tissues are highly variable and suggest that many different tissue-specific transcripts exist, with 9 kb and 6 kb transcripts consistently appearing across tissue types. Between exons 4 (where the translational start site is located) and 25, there is a 4095 base pair open reading frame (ORF) from which the WHSC1-encoding mRNA is transcribed (Stec et al., 1998). In situ hybridization in mouse revealed a specific pattern of WHSC1 expression in the developing nervous system at day 10.5, and expression in brain, ganglia, neural tube, jaw, face, intestinal and lung epithelium, liver, adrenal, and urogenital region at day 13.5. Such an expression pattern is significant given that many of these—notably the brain, jaw, face, and urogenital structures—are affected in the classical WHS phenotype (Stec et al., 1998), and given that the formation of structures of the face and jaw, as well as certain glial cell populations in the brain, depend on neural crest cell migration (Brommer and LeDouarin, 2012). However, WHSC1 function has not yet been explicitly linked to neural crest cell migration.

### 2. WHSC1

Of all the candidate genes, WHSC1 is most often found to be partially or fully monosomic in a majority of clinical cases; however, its absence does not account for the full range of phenotypes associated with the disorder. WHSC1 is a 90 kb gene, two-thirds of which extend into the telomeric end of the 165 kb Wolf-Hirschhorn Syndrome Critical Region. It contains 25 exons and is subject to complex alternative splicing (Stec et al., 1998). Northern blot analysis of expression patterns in human and mouse embryonic and fetal tissues are highly variable and suggest that many different tissue-specific transcripts exist, with 9 kb and 6 kb transcripts consistently appearing across tissue types. Between exons 4 (where the translational start site is located) and 25, there is a 4095 base pair open reading frame (ORF) from which the WHSC1-encoding mRNA is transcribed (Stec et al., 1998). In situ hybridization in mouse revealed a specific pattern of WHSC1 expression in the developing nervous system at day 10.5, and expression in brain, ganglia, neural tube, jaw, face, intestinal and lung epithelium, liver, adrenal, and urogenital region at day 13.5. Such an expression pattern is significant given that many of these—notably the brain, jaw, face, and urogenital structures—are affected in the classical WHS phenotype (Stec et al., 1998), and given that the formation of structures of the face and jaw, as well as certain glial cell populations in the brain, depend on neural crest cell migration (Brommer and LeDouarin, 2012). However, WHSC1 function has not yet been explicitly linked to neural crest cell migration.

#### 2.1. WHSC1 as a histone modifier during development

Although there is a reigning generalization in the field that abnormal WHSC1 dosage is responsible for many of the defining phenotypes of WHS (Bergemann et al., 2005), the question of how it causes such phenotypes remains unanswered. The protein product of this gene is also called MMSET or NSD2, as it is characterized by several domains with known importance to development, including an HMG box, a PHD-type zinc finger domain, and a SET domain, all involved in regulation of transcription during development (Stec et al., 1998). The SET domain possesses methyltransferase capabilities and is common to all but one member of the histone lysine methyltransferase family (Marango et al., 2008; Völkel and Angrand, 2007). Experiments using recombinant NSD proteins have shown that these histone lysine methyltransferases can specifically dimethylate lysine 36 of histone H3.

#### Table 1

WHS candidate genes. For each gene, the potentially WHS-related functions of its protein product are summarized, and relevant references detailing genetic, biochemical, and clinical data related to the gene are listed.

| Gene       | Function                                                                 | References                                                                 |
|------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| TACC3      | Transforming acidic coiled-coil protein: microtubule plus-end tracker, co-factor of the hypoxia inducible factor complex, regulator of epithelial-to-mesenchymal transition and cell migratory behaviors. | Gergely et al., 2000; Groisman et al., 2008; Peset and Vernos, 2008; Simon and Bergemann, 2008; Cyr et al., 2011; Zollino et al., 2014; Nwagbara et al., 2014. |
| FGFR3      | Fibroblast growth factor receptor: involved in neural crest cell chemotaxis, regulator of cell proliferation, cell survival-promoting roles in neural development. | Colvin et al., 1996; Deng et al., 1996; Saarimäki-Vire et al., 2007; Puigilla et al., 2007; Simon and Bergemann, 2008; Katoh and Nakagama, 2014; Sato et al., 2011; Eswarshkumar et al., 2005. |
| LETM1      | Leucine-zipper and EF-hand-containing transmembrane protein: involved in mitochondrial bioenergetics, putative roles in regulating the cell cycle and cellular calcium homeostasis. | Endele et al., 1999; Zollino et al., 2003; Novikovsky et al., 2004; Schlickum et al., 2004; Jiang et al., 2013; Donnan et al., 2014a, 2014b. |
| WHSC1      | Histone H3 lysine methyltransferase: epigenetically influences TWIST transcription, interacts with beta-catenin. | Stec et al., 1998; Toyokawa et al., 2011; Espana et al., 2013. |
| WHSC2      | mRNA processing and cell cycle regulation.                                | Wright et al., 1999. |
(H3K36) given a nucleosome substrate (Li et al., 2009; Venkatesh and Workman, 2013). Additionally, methylation of histone H3 following the transcription of genes associated with this histone (termed co-transcriptional methylation) correlates with the recruitment of histone deacetylase complexes (Venkatesh and Workman, 2013). This is significant because deacetylation and methylation markers at H3—which together suppress untimely transcription initiation—are involved in ensuring the appropriate timing of gene expression. Thus, these marks are especially relevant in early development. Nimura et al. implicate interactions between WHSC1 and cell-type specific transcription factors (TFs) as being responsible for the protein's specific methylation pattern at certain genomic loci: immunoaffinity purification of murine Whsc1-associated proteins—followed by mass spectrometry and pull-down assays—revealed interactions with developmental TFs Sall1, Sall4, and Nanog in ES cells, and Nkx2-5 in embryonic hearts (Nimura et al., 2009). The interactions between WHSC1 and these proteins may prevent inappropriate transcription, as histone deacetylase 1 also interacts with Whsc1-TF complexes and could confer transcriptional repression via the removal of the acetyl mark. This study illuminates one of the many possible functions of WHSC1 in development, and addresses just a few of its possible interactors (Nimura et al., 2009). As indicated by RT-PCR analysis in zebrafish, the mRNA transcript for the homolog DrWhsc1 is present in most adult tissue types (Yamada-Okabe et al., 2010); given its prevalence in both mature and immature cell types, it seems probable that developmentally-regulated transcription factor interactions are just one of many roles of WHSC1 within the cell.

2.2. Involvement of WHSC1 in Wnt signaling

Because WHSC1 is a chromatin modifier, an important question regarding its bigger-picture roles relates to which pathways and processes it might affect at the epigenetic level, under normal conditions as well as in a disease state. The work of Toyokawa et al. provides a preliminary answer. Although the field lacks direct evidence of WHSC1 regulation contributing to craniofacial phenotypes through a specific signaling pathway, they have connected WHSC1 dysregulation to Wnt signaling in the context of cancer (Toyokawa et al., 2011). This group observed upregulation of WHSC1 at the protein level, in addition to elevated levels of its transcribed RNA, in human cancer cell lines. They propose a model in which WHSC1 interaction with beta-catenin is responsible for certain genomic instances of H3K36me3. Specifically, Toyokawa et al. note that H3K36me3 is enriched at the transcriptional start site of CCND1, one indirect target of the beta-catenin-Tcf-4 complex and a downstream effector of Wnt signaling (Sanson et al., 2005; Toyokawa et al., 2011; Fig. 2). Further evidence supporting a role for Wnt dysregulation in WHS was gathered from immunoprecipitation-mass spectrometry, which identified WHSC1 interactors IQGAP1 and beta-catenin (Toyokawa et al., 2011) both of which are involved in Wnt signaling as well as cadherin-mediated cell-cell adhesion and cell migration (Goto et al., 2013; Noritake et al., 2005). It was also reported that nucleus/cytoplasm fractionation assays pinpointed the nucleus as the place of interaction between WHSC1 and beta-catenin (Toyokawa et al., 2011; Fig. 2A). Toyokawa et al. note the possibility that WHSC1 dosage may impact nuclear levels of beta-catenin, in turn affecting canonical Wnt signaling through transcriptional regulation.

The importance of properly-controlled Wnt signaling in developmental cell migration highlights the need for a clearer vision of how WHSC1 dosage impacts this signaling pathway. Particularly significant in migrating neural crest cells are non-canonical Wnt signaling events, which affect Rho/Rac regulation of the actin cytoskeleton, and are a driving force for the generation of planar cell polarity in the migratory neural crest (Mayor and Theveneau, 2014). Planar cell polarity (PCP) signaling depends on the asymmetric localization of molecules, such as non-canonical Wnt11 ligand, the Wnt receptor Frizzled, and the signaling protein Disheveled, to contacts between neighboring cells (Mayor and Theveneau, 2014). In Xenopus, Wnt11 is expressed adjacent and lateral to the early cranial neural crest, and plays an essential role in neural crest cell migration through activation of the PCP pathway (De Calisto et al., 2005). As a whole, PCP signaling allows cell protrusions to form towards open areas within migrating neural crest cell streams, and towards the boundaries of cell populations expressing attractive cues; likewise, it restricts their formation between neighboring cells which have made contact (thus initiating contact inhibition of locomotion), and between cells and surrounding tissues providing repellent signals (Mayor and Theveneau, 2014). As non-canonical Wnt/PCP signaling is necessary for establishing proper directionality of neural crest cell migration (Carmona-Fontaine et al., 2008; De Calisto et al., 2005), its disruption could result in faulty patterns with eventual effects manifesting as craniofacial abnormalities (Fig. 2A).

Further experiments looking specifically at facial morphogenesis have shown that Wnt proteins are powerful regulators of regional facial patterning, and that blocking their activity causes midfacial malformation in chicks (Brugmann et al., 2007). Although it has become clear that canonical Wnt/beta-catenin signaling is vital for neural crest induction (García-Castro et al., 2002; Leung et al., 2016; Wang et al., 2010), the finding that these same Wnt pathways are active in specific populations of delaminating and migrating murine cranial neural crest cells indicates an ongoing role in mammalian facial patterning beyond cell fate specification (Brugmann et al., 2007). In sum, the importance of spatiotemporally-controlled Wnt signaling in embryonic development, and the newly-elucidated connection to WHSC1, qualify both canonical and non-canonical Wnt dysregulation in the neural crest as possible contributors to the orofacial and midline defects observed in the classic WHS phenotype.

2.3. WHSC1 as an epigenetic regulator of Twist expression

Further study of WHSC1 in cancer cell lines strengthens the link between WHS and aberrant cell migration, as the WHSC1 methyltransferase activity has been shown to exert epigenetic control over the expression of Twist family proteins, transcription factors that regulates epithelial-to-mesenchymal transition (EMT) in normal development, as well as in cancer cells (Ezponda et al., 2013; Kuo et al., 2013; Yang et al., 2004; Fig. 2B). As shown by microarray and confirmed by RT-PCR and immunoblot at the RNA and protein levels, WHSC1 is among a small pool of genes which are up-regulated after treatment with resistin, an EMT-inducing paracrine factor secreted by lung tumor-associated dendritic cells in humans (Kuo et al., 2013). In this system, abnormally high WHSC1 dosage causes dimethylation of histone H3K36 and decreased trimethylation of H3K27, an epigenetic combination which then enhances the expression of the transcription factor Twist. As a master regulator of EMT, Twist drives a change in cellular identity by initiating large-scale changes in gene expression; in the case of these WHSC1 over-expressing cell lines, overactive Twist likely explains the enhanced migration and invasion behaviors observed by Kuo et al. Importantly, there was no change in proliferation levels, affirming that altered cell migration is the major WHSC1 over-expression phenotype of developmental relevance (Kuo et al., 2013). Twist hyperactivity has also been shown in prostate cancer as a result of WHSC1 over-expression: WHSC1 binds to the TWIST1 locus to activate its expression by means of increased H3K36 dimethylation. Thus, when TWIST1 is knocked down in WHSC1-over-expressing RWPE-1 cells, EMT and invasion are prevented (Ezponda et al., 2013). Considering these data, there is strong support that aspects of the WHS phenotype result from aberrantly regulated EMT and, subsequently, cell migration.
2.4. Neural crest cell migration is regulated by histone H3 methyltransferases

Neural crest cells rely on continuous epigenetic modifications to drive changes in gene expression during their migration (Hu et al., 2014). WHSC1L1—the paralog of WHSC1 found on chromosome 8—is a major NSD-family histone methyltransferase thought to facilitate such changes at H3K36 of the neural crest cell transcription factor Sox10 (Jacques-Fricke and Gammill, 2014). Electroporating chick embryos before neural crest cell migration with a dominant negative construct lacking the methylating SET domain resulted in faulty migration: cells began to travel away from the neural tube but stopped short of their destination points (Jacques-Fricke and Gammill, 2014). Additionally, this dominant negative construct disrupted specification, preventing the expression of genes involved in neural crest cell specification and migration. Thus, chromosome 4p deletions characteristic of WHS may indeed impact neural crest development, especially considering the similar structures and functions conserved from WHSC1L1 and WHSC1, the 4p gene from which it arose by way of a duplication event (Stec et al., 2001).

2.5. Future directions: mechanistically interrogating the role of WHSC1 in cell motility

What still remains uncertain are the exact mechanisms through which WHSC1 impacts cell motility. One study in a multiple myeloma cell line marked by a genetic translocation causing WHSC1 up-regulation showed that WHSC1 knockdown led to cell cycle arrest, decreased proliferative activity, and inhibited extracellular matrix adherence (Lauring et al., 2008). Thus, regulation of cell adhesion is one possible mechanism. Moreover, siRNA-mediated knockdown of WHSC1 decreased expression levels of genes involved in cell adhesion, namely DSG2, a component of desmosomes also known to impact proliferation and signaling, and ADAM9, a metalloproteinase which interacts with αβ5 integrin and promotes substrate adhesion (Brito et al., 2009). Further study will be needed to corroborate the link between WHSC1 dysregulation and adhesion-mediated defects in motility.
3. LETM1

LETM1 is a gene located less than 80 kb distal to the minimal WHS critical region between WHSC1 and FGFR3, and it is deleted in most WHS patients (Endele et al., 1999). After initial cloning and characterization of the gene, a putative protein was inferred from its sequence, and it was predicted to have several coiled-coil regions and a leucine zipper as its defining structural features; its sequence homology grouped it with the EF-hand calcium-binding protein family (Endele et al., 1999). Subsequent work examined its conserved expression and localization from yeast to vertebrates and revealed that, in mouse embryonic fibroblasts and in yeast, LETM1 and its ortholog, YOLO27, encode integral proteins found in the inner mitochondrial membrane (Nowikovsky et al., 2004). Conservation of protein function was also examined between human and yeast homologs; Yolo27-deficient yeast could be rescued by expression of human LETM1, suggesting that human LETM1 is also targeted to yeast mitochondria and restores the function of its missing ortholog (Nowikovsky et al., 2004).

3.1. LETM1 as a component of a new WHS critical region

In keeping with the trajectory of WHS research thus far, recent investigation into LETM1 has attempted to reconcile questions of protein function with an ever-shifting understanding of the disorder’s genetic roots, often gained from phenotypic and genotypic analysis of a small sample of human patients. The expansion of the WHS critical region is one important instance: a second, larger WHS critical region was defined by Zollino et al. in 2003. It falls within a 300–600-kb interval in 4p16.3, between loci D4S3327 and D4S98-D4S168, and includes LETM1 (Zollino et al., 2003). Such an expansion accommodates not only the phenotype-genotype correlations observed in the patients described by Zollino et al.—who exhibited WHS hallmarks such as seizures, microcephaly, abnormal facial appearance, and growth delay, despite having an intact WHS critical region—but also a patient documented in Rauch et al., whose critical region exhibited a 191.5-kb deletion which left LETM1 unaffected (Rauch et al., 2001). This patient’s minor growth and learning impairment, distinct facial morphology, and marked lack of seizures have led many to postulate that LETM1 genetic irregularities account for the neuromuscular manifestations of WHS, while other candidate genes in the critical region contribute to additional aspects of the phenotype.

3.2. LETM1 deficiency and mitochondrial dysfunction

Addressing the hypothesis that LETM1 dosage affects seizure propensity in WHS patients began with the acquisition of a basic structure-function understanding of the protein: using an EGFP-tagged human LETM1 construct transfected into HEK293 cells, Schlickum et al. corroborated the mitochondrial localization reported by Nowikovsky et al. Moreover, a 167-amino acid deletion at the amino terminus of LETM1 revealed this segment to be the mitochondrial targeting sequence of the protein (Schlickum et al., 2004). The important question of what role LETM1 plays in the inner mitochondrial membrane, and how it may contribute to seizure phenotypes, was pioneered by Jiang et al. (Jiang et al., 2013). Although mitochondrial morphology was similar in primary fibroblast cultures from LETM1 heterozygous knockout mice and WT mice, mitochondria from the heterozygous mutants exhibited altered calcium metabolism and pH compared to those of WT (Jiang et al., 2013). Additionally, LETM1-deficient fibroblasts took up less oxygen than controls in a low-glucose environment, implying a role for LETM1 in the efficiency of glucose oxidation. This notion was supported by tissue-specific analysis of ATP concentrations, which demonstrated a 27% reduction in brain ATP (Jiang et al., 2013). The group subsequently investigated how LETM1 dosage contributes to seizure tendencies in mice, demonstrating seizure scores for LETM1 hemizygous knockout mice to be 1.5-fold higher than that of WT, and their brain ATP concentrations to be reduced by 25% following induced seizures. While the in vitro experiments in this study significantly advanced the field’s understanding of the biochemistry of LETM1, these in vivo experiments prominently accent the void of cell biological data linking seizure propensity with LETM1-mediated mitochondrial dysfunction.

3.3. Potential effects of LETM1 dosage on cellular metabolism

As the downstream effects of cellular calcium and oxygen flux are far-ranging and varied based on cell type, it is prudent to assume that LETM1 dosage may contribute to the WHS phenotype in ways that are separate from its putative role in seizure-causing depolarization. Recently, Doonan et al. have observed altered mitochondrial calcium influx and efflux, mitochondrial bioenergetics, and metabolic signaling when LETM1 is silenced in multiple organisms and cell types, including in cells derived from WHS patients; they also report AMPK activation and increased mitochondrial ROS production (Doonan et al., 2014a). While the primary takeaway from this study is that further work is needed in order to associate these metabolic trends with the particulars of the WHS pathophysiology, the identification of such trends is invaluable as a jumping-off point for future studies. Perhaps the group’s most salient observation is the one regarding ROS production, as this phenomenon underlies neurodegeneration in a broad spectrum of diseases, including Alzheimer’s and ALS (Dasuri et al., 2013). The idea that events downstream of ROS production could impact a variety of motile cells just as readily as they affect neuronal networks implies another potential link to the transcription factor Twist (Fig. 2B). Twist is activated by hypoxia-inducible factor (HIF) 1 (Yang and Wu, 2008), and ROS production under hypoxic conditions is necessary and sufficient for HIF activation (Chandel et al., 1998, 2000). Given that LETM1 deficiency impairs oxygen consumption and increases ROS production (Doonan et al., 2014b), a pathological role for HIF complexes upstream of Twist is not out of the question. It is possible that—due to some metabolic irregularity resulting from improper LETM1 dosage—Twist upregulates mesenchymal phenotypic markers to override normal physiological controls and induce untimely migration events at key moments in development.

4. FGFR3

Fibroblast growth factor receptor 3 (FGFR3) is one of the four homologous receptors of the FGFR subgroup, belonging to the receptor tyrosine kinase family. Its activation is associated with cellular processes such as proliferation, migration, cell survival, and wound healing (Eswarakumar et al., 2005). The receptor is activated following dimerization of monomers and subsequent trans-autophosphorylation of the kinase domain, ultimately activating RAS-MAPK, P13-AKT, and JAK/STAT signaling cascade (Eswarakumar et al., 2005). While roles for FGFR receptors in cancer-related processes, such as inappropriate migration and proliferation, have been comprehensively reviewed (Katoh and Nakagama, 2014), less attention has been paid to the cell biological ramifications of FGFR3 absence as it specifically relates to early development.

4.1. Effects of FGFR3 deficiency in murine development

As FGFR3 is located in the vicinity of the WHS critical region, homozygous null mouse lines have been created for phenotypic assessment, and these have recapitulated some of the skeletal malformation seen in human patients with WHS (Simon and Bergemann, 2008; Fig. 3). Kyphosis (abnormal spine curvature), elongated tails, and malformed femurs are characteristics of homozygous null mice (Colvin et al., 1996; Deng et al., 1996), suggesting that murine Fgfr3 is involved in inhibiting chondrocyte proliferation (Colvin et al., 1996; Deng et al., 1996; Simon and Bergemann, 2008). Hearing problems
4.2. FGFR3 in the context of its growth receptor family

Because of the existence of four FGFR homologs in both mice and humans, it is possible that the activities of FGFR3 in particular vary between human and murine tissues, depending on unknown degrees of functional redundancy. Moreover, while studies in mice have helped to dissect out FGFR-specific phenotypes—something that has not been possible in human patients with deletions that encompass multiple genes of the WHS critical region—the cell biological roots of these phenotypes remain unclear. It seems likely, based on basic principles of skeletal development, that FGFR-related skeletal defects may primarily result from problematic regulation of proliferation; however, the roles of FGFRs in other tissues and cell types are less clear. Interestingly, FGFRs 1 and 3 have recently been implicated in the chemotactic response of cardiac neural crest cells to FGFR8 in the pharyngeal ectoderm in chick embryos, operating upstream of the MAPK/ERK pathway (Sato et al., 2011). Loss of FGFR1 or FGFR3 activity in this context resulted in slower neural crest migration velocities and a tendency for cells to die closer to the neural tube (Sato et al., 2011). These defects due to reduction in FRFR3 function likely have repercussions in cardiac development, which might explain the heart dysfunction characteristic of human WHS. More comprehensive studies on FGFR dose dependence in specific developmental processes will be integral to exploring this possibility.

5. TACC3

The transforming acidic coiled-coil protein 3 is yet another example of a protein whose dosage may contribute to the WHS phenotype through several mechanisms, including one related to its role in cell motility and migration. Although TACC3 need not be affected for a traditional WHS diagnosis to be made, its putative role in facial development and its proximity to the WHS critical region is enough to single it out as a possible culprit in aspects of the pathology. TACC3 is a microtubule associated protein which localizes to the centrosome and mitotic spindle (Gergely et al., 2000; Groisman et al., 2000; Peset and Vernos, 2008). It was recently shown to act as a plus-end tracking protein (+TIP) on the ends of polymerizing microtubules, where it associates with the microtubule polymerase, XMAP215, and affects microtubule dynamics in Xenopus embryonic cells (Gutiérrez-Caballero et al., 2015; Nwagbara et al., 2014). Consistently, TACC3-depleted HeLa cells have shown destabilized microtubules, mitotic arrest, and improper chromosome arrangement (Gergely et al., 2003; Schneider et al., 2007). The question of how TACC3 dosage impacts craniofacial development in vivo is particularly timely, as it was recently shown that TACC3 mRNA is highly expressed in migratory neural crest cells in the Xenopus laevis pharyngeal arches; other TACC family members' transcripts (TACC1 and TACC2) did not mirror this craniofacial expression pattern (Rutherford et al., 2016). Despite its documented roles in cytoskeletal regulation, the ways in which TACC3 expression levels contribute to gross morphological phenotypes have not yet been described.

5.1. TACC3 and WHS genetics

The implication of TACC3 in WHS was most recently validated by a case study in which a patient's microduplication on chromosome 4p resulted in extra copies of FGFR3, LETM1, and TACC3 (Cyr et al., 2011). The duplication notably did not affect WHSC1 or WHSC2. Duplication, instead of deletion, as a cause of WHS has been described elsewhere (Hannes et al., 2010), but as Cyr et al. points out, this earlier-reported duplication did in fact encompass WHSC1 in addition to other genes such as TACC3, and so it seemed unclear which genes within the duplicated region accounted for the observed phenotype. Although it is difficult to draw general conclusions from individual patients, it has been suggested that heightened dosage of TACC3 may
somewhat contribute to neurodevelopmental delay (Cyr et al., 2011).

There are currently no mouse models that recapitulate any TACC3-encompassing microduplications resulting in WHS-like phenotypes, although there are models presenting evidence of skeletal and craniofacial malformation upon TACC3 deletion (Piekorz et al., 2002) (Fig. 3). In a study by Piekorz et al., two-thirds of the homozygous null embryonic mice which were not lethally affected by TACC3 knockout exhibited facial clefts, in addition to growth retardation leaving many organs underdeveloped compared to controls (Piekorz et al., 2002). Mice homozygous for hypomorphic mutations have been used to study the effects of TACC3 deficiency in early development, as embryonic lethality is common in homozygous null mice: pups die just after birth and exhibit intrauterine growth retardation, as well as defects in formation of the axial skeleton, while their primary fibroblasts show defective mitosis marked by improper chromosome alignment (Yao et al., 2007). Despite the convincing evidence that TACC3 deficiency correlates with craniofacial malformation in mice, there are limited clinical examples of TACC3 deletions in WHS-presenting human patients. One subject in a clinical study was affected by a 4p16.3 deletion encompassing WHSC1, LETM1, TACC3, FGFR3, and thirteen additional transcribed genes (Zollino et al., 2014). This four-year-old boy exhibited facial irregularities and a growth delay characteristic of WHS, although his lack of seizures is puzzling given the previously discussed evidence for LETM1 deficiency. SNP array analysis for another case, a 2-year old showing developmental delay, revealed a deletion on 4p16.3 which encompassed the first three exons of TACC3 (Engbers et al., 2009). This patient exhibited facial characteristics associated with WHS, although she lacked microcephaly, and showed only mild mental retardation. Interestingly, this patient’s deletion did not affect WHSC1, suggesting that other candidate genes including TACC3 may play important roles in facial phenotypes such as the characteristic short philtrum and downturned mouth (Engbers et al., 2009).

5.2. Linking TACC3 with spindle morphology and microcephaly

The importance of TACC3 at the mitotic spindle calls to attention a particular phenotype characteristic of WHS: microcephaly, or reduced occipital frontal circumference, is a well-documented consequence of spindle dysregulation (Kerzdorfer et al., 2013; Mahmood et al., 2011; Megraw et al., 2011; Thornton and Woods, 2009; Fig. 2C). The link between microcephaly and spindle pole microtubules is substantiated by the observation that all microtubule-associated genetic defects identified thus far involve proteins with known or predicted roles in forming or maintaining centrosomes and the spindle apparatus (Kerzdorfer et al., 2013). The influence that spindle regulation has on determination of cerebral size is perhaps most clear in the example of ASPM, or abnormal spindle-like microcephaly-associated protein. Knockdown of ASPM by RNA interference in mouse neuroepithelial cells results in skewed spindle pole orientation, preventing one daughter cell from inheriting apical membrane and ultimately preventing the pool of neuroepithelial progenitors from expanding; this reduced progenitor pool size could very well be an early developmental determinant of microcephaly (Fish et al., 2006). As Kerzdorfer et al. point out, progenitor cells’ transition from symmetric to asymmetric division is tightly regulated, so that differentiation and subsequent migration to the appropriate tissue occur normally (Kerzdorfer et al., 2013). Going forward, it will be constructive to examine whether TACC3 and other plus-end tracking proteins (+TIPs) at the mitotic spindle are capable of altering its morphology such that cell fate and migration are impacted, and whether changes in these processes contribute to the defects seen in WHS.

5.3. TACC3 involvement in epithelial-to-mesenchymal transition

Recent work has suggested a more direct role for TACC3 in cell migration, similar to some of its WHS-related neighbors encoded on chromosome 4p. Most strikingly, TACC3-over-expressing HeLa cells exhibited up-regulation of mesenchymal markers and corresponding down-regulation of epithelial ones, as well as a distinctly elongated and spindle-like morphology characteristic of EMT (Ha et al., 2013). Additional phenotypes included enhanced proliferation and growth on agar, enhanced migration as determined by transwell assays, and enhanced invasion as shown through a matrigel invasion assay; the same trends were reported for TACC3-over-expressing HEK293 cells and U2OS cells (Ha et al., 2013). TACC3 was also found to be linked with the activity of beta-catenin: reporter assays demonstrated enhanced beta-catenin activity in TACC3-over-expressing cells, and Western blot analysis strengthened this finding by revealing heightened expression (Ha et al., 2013). Immunofluorescence experiments performed by Ha et al. illuminate a possible connection to WHSC1: TACC3 over-expression results in increased nuclear localization of beta-catenin compared to controls (Fig. 2A), and the nucleus is where WHSC1-beta-catenin association is reported to be most prevalent (Toyokawa et al., 2011). Taken together with the mounting evidence detailing beta-catenin’s relationship to EMT (Kim et al., 2002), its heightened nuclear localization following TACC3 over-expression highlights a possible regulatory role for TACC3 upstream of the WHSC1-beta-catenin complex.

5.4. Future directions for investigating the role of TACC3 in WHS

Looking ahead, it will be worthwhile to consider alternative ways in which TACC3 could contribute to WHS pathophysiology. As TACC3 was first identified in a screen for interactors of the hypoxia-responsive ARNT (aryl hydrocarbon receptor nuclear translator) protein (Sadek et al., 2000), and it has since been shown that TACC3 coiled-coils are a necessary co-factor for HIF complex assembly (Guo et al., 2015; Fig. 2B), TACC3 levels likely affect the integrity of the hypoxic response. Because oxygen levels are tightly regulated during embryonic development, it is imperative (as in the case of altered bioenergetics due to LETM1 deficiency) to consider the effect that their dysregulated fluctuation may have on migration events, among other processes pivotal to development.

The multitude of ways that TACC3 impacts development—cell cycle regulation, microtubule dynamics, organized migration, and possibly hypoxia—merit further investigation in the context of WHS. It is worth noting that paralogous proteins TACC1 and TACC2 have been implicated in certain carcinomas, and thus could also impact migration (Conte et al., 2003; Gangisetty et al., 2004; Kimura and Okano, 2005; Takayama et al., 2012). Recently, TACC1 and TACC2 were revealed to possess plus-tip-tracking activity and the ability to influence MT dynamics in a manner similar to TACC3 (Lucaj et al., 2015; Rutherford et al., 2016). Given the homology between members of the TACC family, future work must be done to investigate the specific mechanisms by which the TACC family regulates developmental processes, with a special emphasis on whether TACCs 1 and 2 can rescue any disease phenotypes associated with TACC3-deficient cases of WHS. As for the possibility that TACC3 may impact the WHS phenotype in a manner dependent on the dosages of other WHS genes, the identification of an FGFR3-TACC3 fusion protein in human cancer cells has provided some initial insight (Carneiro et al., 2015). The oncogenic capacity of this fusion suggests that the activities of these two proteins are related in a way that is physiologically relevant to cancer progression; thus, although not fused in normal development, varied gene dosage due to WHS deletions may have a significant impact on processes lying downstream of both TACC3 and FGFR3 regulation.

5.5. Summary and future investigations

In conclusion, WHS is a developmental disorder with well-defined genetic causes, yet characterizing its cell biological profile remains an
important barrier which must be broken to encourage successful clinical advances in the future. This review has focused on a series of genes on chromosome 4 whose sequential order is conserved at a second loci (on chromosome 8) within the human genome, and we have examined the roles of their protein products as described in the literature as a means of elucidating a cell migration-based functional relationship. The neural crest, a multipotent, migratory stem cell population, has been highlighted as an excellent candidate for relaying genotypic aberrations of WHS to the structural, phenotypic level. Future studies looking into the mechanistic roles of TACC3, LETM1, FGFR3, and WHSC1 may reveal an interrelatedness between the levels of epigenetic modifications, intracellular signaling, and cytogenetic regulation in the progression of the WHS disorder. Clarifying these intersecting cell biological irregularities will be indispensable in designing preventative and interventional therapies in the future.

At the most basic and immediate level, it will be informative to perform multiple WHS-mimicking genetic manipulations in tandem: this will mean creating animal models which either lack or contain extra WHS candidate genes in various combinations. Certain mouse lines already exist which could be utilized as a jumping-off point. For instance, mice that are homozygous null for Fgfr3, Lettm1, or Tacc3 alone currently exist (Simon and Bergemann, 2008). Simon and Bergemann have already articulated the need for polygenic models of WHS on the basis of the transcription factor/co-factor relationship of many WHS-implicated proteins such as Tacc3 and Ctbp1, whose shared interaction with transcription factor FOG-I implies a relationship at the genetic level (Garriga-Canut and Orkin, 2004; Katz et al., 2002; Simon and Bergemann, 2008). In order to specifically interrogate motility-based defects in WHS, multigenic mouse models with mutations targeting the proteins reviewed here should be pursued. This represents an addendum to the work suggested by Simon and Bergemann, and a call for a more nuanced interrogation of how key cell biological processes such as signaling pathways and protein–protein interactions contribute to the WHS phenotype.

An equally important benchmark for the WHS field to push towards in the coming years will be the diversification of model systems used to study the disorder. While mouse models have facilitated the majority of our current insights into its phenotype, and are particularly useful in that they allow for genotype-phenotype correlations which closely recapitulate the human disorder, no model has perfectly recreated the human phenotype (Fig. 3). Examining WHS candidate proteins in other systems may force us to consider significant details that have been overlooked at the cellular level. The Xenopus model system in particular has many merits as a tool to study development: the cranial neural crest and other neural cell types can easily be isolated and maintained in culture, allowing for a variety of migration and protein localization assays (DeSimone et al., 2005; Lowery et al., 2012; Milet and Monsoro-Burq, 2014). Moreover, facial cartilage forms in early tadpoles only a few days after oocyte fertilization, thus its morphology in vivo can be examined with unparalleled time efficiency. Quantitative morphometric analysis methods, optimized for the tadpole craniofacial area, also exist (Kennedy and Dickinson, 2014). With a new and broader perspective on both the modeling of WHS and the possible intricacies of its cell biology, it will be possible to better understand how the disorder progresses and to move toward the ultimate goal of disrupting such mechanisms.

Acknowledgements

We thank members of the Lowery Lab for helpful comments and critiques.

Funding

This work was supported by the National Institutes of Health [R00 MH095768, R03 DE025824], March of Dimes [#1-FY16-220], and American Cancer Society – Ellison Foundation Research Scholar Grant [RSG-16–144-01-CSR].

References

Battaglia, A., Carey, J.C., South, S.T., 2015. Wolf-Hirschhorn syndrome: a review and update. Am. J. Med Genet C. Semin. Med. Genet. 169, 216–223.
Bergemann, A.D., Cole, F., Hirschhorn, K., 2005. The etiology of Wolf-Hirschhorn syndrome. Trends Genet. 21, 189–195.
Brauli, V., Moore, R., Kutsch, S., Ishibashi, M., Rowitch, D.H., McMahon, A.P., Sommer, L., Boudaoud, O., Kemler, R., 2001. Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 128, 1253–1264.
Brito, J.L., Walker, B., Jenner, M., Dickens, N.J., Brown, N.J., Ross, F.M., Avramidou, A., Irving, J.A., Gonzalez, D., Davies, E.F., Morgan, G.J., 2009. MMSET deregulation affects cell cycle progression and adhesion regulations in (4;14) myeloma plasma cells. Haematologica 94, 78–86.
Bronner, M.E., LeDouarin, N.M., 2012. Development and evolution of the neural crest: an overview. Dev. Biol. 366, 2–9.
Brugmann, S.A., Goodough, L.H., Gregoireff, A., Leucht, P., ten Berge, D., Fuerer, C., Clevers, H., Niuse, R., Helms, J.A., 2007. Wnt signaling mediates regional specification in the vertebrate face. Development 134, 3283–3295.
Carmona-Fontaine, C., Matthews, H., Mayor, R., 2008. Directional cell migration in vivo: Wnt at the crest. Cell Adhes. Migr. 2, 240–242.
Carrington, A., Elvin, J.A., Koppoth, S., de la Maza, P., Adlam, A.S., Restrepo, A., Berry, E., Giles, F.J., Johnson, M.L., 2015. FGFR3-TACC3: a novel gene fusion in cervical cancer. Gynecol. Oncol. Rep. 13, 53–56.
Chandel, N.S., Maltepe, E., Goldwasser, E., Mathieu, C.E., Simon, M.C., Schumacker, P.T., 1998. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. USA 95, 11175–11120.
Chandel, N.S., McIntosh, D.S., Feliciano, C.E., Wood, T.M., Melendez, J.A., Rodriguez, A.M., Schumacker, P.T., 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J. Biol. Chem. 275, 25130–25138.
Colvin, J.S., Bohn, B.A., Harding, G.W., McEwen, O.G., Ornitz, D.M., 1996. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet. 12, 390–397.
Conte, N., Delaval, B., Génestier, C., Ferrand, A., Isnardon, D., Larroque, C., Prigent, C., Seraphin, B., Jacquemier, J., Birnbaum, D., 2003. TACCI-chTOD-Aurora A protein complex regulates cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Proc. Natl. Acad. Sci. USA 100, 11718–11723.
Cooper, H.L., Hirschhorn, K., 1961. Abnormal deletion of short arms of one chromosome (4 or 5) in a child with defects of midline fusion. Mamm. Chromosom. 4.
Cyr, A.B., Nimmakayalu, M., Longmuir, S.Q., Patil, S.R., Kepple-Nonreuil, K.M., Nicholshchov, O.A., 2011. A novel 4p16.3 microduplication distal to WHSC1 and WHSC2 characterized by oligonucleotide array with new phenotypic features. Am. J. Med. Genet. A 155A, 2224–2228.
Dasuri, K., Zhang, L., Keller, J.N., 2013. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic. Biol. Med. 62, 170–185.
De Calisto, J., Araya, C., Marchant, L., Riaz, C.F., Mayor, R., 2005. Essential role of non-canonical Wnt signaing in neural crest migration. Development 132, 2587–2597.
Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., Leder, P., 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911–921.
DeSimone, D.W., Davidson, L., Marsden, M., Alfdandi, D., 2005. The Xenopus embryo as a model system for studies of cell migration. Methods Mol. Biol. 294, 235–245.
Doonan, P.J., Chandramouorthy, H.C., Hoffman, N.E., Zhang, X., Cárdenas, C., Shanmugapriya, S., Rajan, S., Vallem, S., Chen, X., Foskett, J.K., Cheung, J.Y., Houser, S.R., Mades, M., 2014a. LETM1-dependent mitochondrial Ca2+ flux modulates cellular bioenergetics and proliferation. FASEB J. 28, 4946–4949.
Endele, S., Fuhry, M., Pak, S.J.B., Zabel, R.U., Winterspach, A., 1999. LETM1, a novel gene encoding a putative EF-hand Ca2+(binding) protein, links the Wolf-Hirschhorn syndrome (WHHS) critical region and is deleted in most WHS patients. Genomics 60, 218–225.
Engbers, H., van der Smagt, J.J., van ‘t Slot, R., Vermeesch, J.R., Hochstenbach, R., Poot, M., 2009. Wolf-Hirschhorn syndrome facial dysmorphic features in a patient with a t(4;14) deletion tetrasomic to the WHSCR and WHSCR 2 regions. Eur. J. Hum. Genet. 17, 129–132.
Eswarakumar, V.P., Lax, I., Schlessinger, J., 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139–149.
Espinosa, T., Popovic, R., Shah, M.Y., Martinez-Garcia, E., Zheng, Y., Min, D.J., Will, C., Neri, A., Kelleher, N.L., Yu, J., Licht, D.J., 2013. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 32, 2882–2890.
Fisch, J.L., Kosodo, Y., Endrad, W., Paabo, S., Huttner, W.B., 2006. Aspm specifically maintains symmetric proliferative divisions of neuroepithelial cells. Proc. Natl. Acad. Sci. USA 103, 10438–10443.
Gangisetty, O., Lauffert, B., Sondarva, G.V., Chelsea, D.M., Still, I.H., 2004. The transforming acidic coiled coil proteins interact with nuclear histone acetyltransferases. Oncogene 23, 2559–2563.
Garcia-Castro, M.I., Marcelle, C., Bronner-Fraser, M. 2002. Ectodermal Wnt function as a neural crest inducer. Science 297, 848–851.

Garriga-Canals, M., Orkin, S.H. 2004. Transforming acidic coiled-coil protein 3 (TACC3) controls friends of GATA (FOG1) subcellular localization and regulates the association between GATA-1 and FOG1 during hematopoiesis. J. Biol. Chem. 279, 23597–23605.

Gergely, F., Draviam, V.M., Raff, J.W. 2003. The ch-TOG/XMAP215 protein is essential for prophase I chromosome pole formation in human somatic cells. Genes Dev. 17, 336–341.

Gergely, F., Karlsson, C., Still, I., Cowell, J., Kilmartin, J., Rak, P. 2001. First Delphi survey on multidrug resistance genes. Trends Pharmacol. Sci. 22, 409–414.

Goto, S., Tato, A., Adachi, S., Nakamura, Y., Schwartz, R.J., Kaneda, Y., 2009. Histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 460, 776–780.

Gottlieb, C., Feng, F., Ishikawa, K., Bertuzzi, S., Dabdoub, A., Griffith, A.J., Fritzsch, B., Kelley, M.W. 2007. Disruption of fibroblast growth factor receptor 3 signaling results in defects in cellular differentiation, neuronal patterning, and hearing impairment. Dev. Dyn. 236, 1905–1917.

Gurusiddaiah, N., Kuo, C.H., Chen, K.F., Chou, S.H., Huang, Y.F., Wu, C.Y., Cheng, D.E., Chen, Y.W., Yang, J. 2011. The H3K36 dimethyltransferase SETD2 promotes cancer cell migration and growth. Cancer Cell 20, 522–534.

Ha, G.H., Park, J.S., Bruner, E.K. 2013. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERM signaling pathways. Cancer Lett. 326, 63–75.

Hammer, R., Droumiotopoulos, J., Vermeesch, J.R., Haus, O., 2010. Duplication of the Wolf-Hirschhorn syndrome. Proc. Natl. Acad. Sci. USA 110, E2249–E2254.

Hansen, A.F., Ruvolo, S.P., Lowery, L.A., 2015. Xenopus TACC1 is a microtubule plus-end tracking protein that promotes axon elongation and also regulates microtubule plus-end dynamics in multiple embryonic cell types. Mol. Biol. Cell 26, 7851–7862.

Heide, J., Heih-Jn., I.H. 2002. The centromeric protein TACC is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J. 21, 6513–6521.

Henke, F.W., Neumann, R.E., Aitola, M., Pelto-Huikko, M., Gustafsson, J.A. 2003. Identification of the androgen-responsive cell signaling network regulating androgen-induced cell proliferation and castration-resistant growth of prostate cancer. Mol. Endocrinol. 26, 748–761.

Hirschhorn, J.R., Beattie, M.S., Karmali, A.A., Hammer, R., Droumiotopoulos, J., Haus, O. 2010. The double-strand break repair enzyme mre11alpha is required for initiation of mitotic sister chromatid cohesion. Proc. Natl. Acad. Sci. USA 107, 10674–10679.

Hutson, M.R., Kirby, M.L. 2011. FGF8 signaling is chemotactic for cardiac neural crest progenitors through activation of the PI3K/Akt pathway. Dev. Biol. 361, 1082–1093.

Iwaki, K., Urano, T., Ikeda, K., Fujisawa, T., Takahashi, S., Homma, Y., Ouchi, Y., Inoue, T. 2012. TACC2 is an androgen-responsive cell signaling network regulating androgen-mediated and castration-resistant growth of prostate cancer. Mol. Endocrinol. 26, 748–761.

J. W., Costa, J.L., Naranjo, C., Francis-West, P., Altherr, M.R. 1999. Comparative genomic hybridization analysis of constitutional chromosome abnormalities in patients with congenital developmental abnormalities. Humangenetik 1, 397–413.

Kaczorowski, J.W., Angrand, P.O. 2007. The control of histone lysine methylation in epigenetic control of cell division. Annu. Rev. Genet. 41, 721–751.

Kakehata, E., Aikawa, M., Takahashi, A., Sato, F. 2003. The function of cyclin D1 in neural crest cell sorting is regulated by the DVL2–DAPK1 protein complex. Development 130, 4371–4385.

Kaneda, Y., Ryoga, Y., Shiohara, T., Sawamura, Y., Kato, S. 2004. Recruitment of TACC protein to the mitotic spindle is essential for developmentally regulated chromosome alignment. J. Biol. Chem. 279, 30315–30320.

Kato, N., Dhom, B., Brugnara, C., Litt, M., Torres, C. 2010. Transcription elongation and implications in organismal development. Wiley Interdiscip. Rev. Dev. Biol. 2, 685–708.

Keller, P., Ebbert, P.T. 2014. Wolf-Hirschhorn syndrome: Clinical manifestations, genetic heterogeneity and mutation spectrum. Orphanet J. Rare Dis. 6, 39.

Kino, T., Tokuda, K., Horio, T., Hishinuma, M., Kishida, M. 2000. The Drosophila forkhead gene forkhead is essential for neural border intermediate. Development 127, 398–410.

Koide, Y., Wada, T., Ohara, S., Sugimura, H., Kato, H., Nakamura, Y. 2013. The forkhead transcription factor Foxd3 is required for postnatal neural tube closure. Proc. Natl. Acad. Sci. USA 110, 3429–3434.

Kornblau, S.M., Moghekar, A., Simpson, J.C., Steglich, C., O'Brien, R.J., Winterpacht, A., Endele, S.U. 2004. LETM1, a gene deleted in Wolf-Hirschhorn syndrome, encodes an evolutionarily conserved mitochondrial protein. Genomics 83, 254–261.

Kouzarides, T. 2007. Histone lysine methyltransferases. Nat. Rev. Mol. Cell Biol. 8, 275–286.

Kuratsu, J., Takahashi, H., Yasuda, K. 2004. The TACC2 protein promotes invasion of Wnt signaling-dependent cell proliferation. Cell 116, 342–353.

Kuo, C.H., Chen, K.F., Chou, S.H., Huang, Y.F., Wu, C.Y., Cheng, D.E., Chen, Y.W., Yang, J.H., Huang, Y.J., Huang, M.S. 2013. Lung tumor-associated dendritic cell-derived retinoid promotes tumor cell proliferation through Wnt signaling and inactivation of the Fas protein. J. Pathol. 229, 475–488.

Kwak, W.-J., Choi, B.-K., Nam, J.-H., An, J.-H., Lee, J.W., Park, J.S., Lee, J.-H., Kim, Y.-H. 2012. TACC2 is an androgen-responsive cell signaling network regulating androgen-mediated and castration-resistant growth of prostate cancer. Mol. Endocrinol. 26, 748–761.
Yao, R., Natsume, Y., Noda, T., 2007. TACC3 is required for the proper mitosis of sclerotome mesenchymal cells during formation of the axial skeleton. Cancer Sci. 98, 555–562.

Zollino, M., Lecce, R., Fischetto, R., Murdolo, M., Faravelli, F., Selicorni, A., Butte, C., Memo, L., Capovilla, G., Neri, G., 2003. Mapping the Wolf-Hirschhorn syndrome phenotype outside the currently accepted WHS critical region and defining a new critical region, WHSCR-2. Am. J. Hum. Genet. 72, 590–597.

Zollino, M., Orteschi, D., Ruiter, M., Pflund, R., Steinl, K., Cufiero, C., Ricciardi, S., Contaldo, I., Chiefo, D., Ranalli, D., Acquaafondata, C., Murdolo, M., Marangi, G., Asaro, A., Battaglia, D., 2014. Unusual 4p16.3 deletions suggest an additional chromosome region for the Wolf-Hirschhorn syndrome-associated seizures disorder. Epilepsia 55, 849–857.